Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cellex Inc
Finance Watch: Blackstone Closes $1.6bn Fund To Back Commercial-Stage Companies
Public Company Edition: Blackstone Life Sciences Yield will finance approved products, while the firm’s prior fund supports late-stage programs. Also, Coeptis will merge with a SPAC, Bausch + Lomb secured post-IPO debt, and BioXcel revealed a $260m financing and new subsidiary.
Intellia, Cellex Team Up On New CAR-T Firm, Backed By Blackstone
Blackstone is providing $250m to combine Intellia’s gene editing and Cellex’s cell manufacturing capabilities in a new CAR-T company using Cellex subsidiary GEMoaB’s technology and pipeline as a foundation.
- Medical Devices
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.